Chemed [CHE] vs Amedisys [AMED] Detailed Stock Comparison
Chemed
NYSE
Loading...
Amedisys
NASDAQ
Loading...
TLDR: Quick Comparison Summary
Based on 20 vital metrics comparison: Chemed wins in 11 metrics, Amedisys wins in 8 metrics, with 0 ties. Chemed appears stronger overall.
View Metrics Details
Vital Metrics Comparison
| Metric | Chemed | Amedisys | Better |
|---|---|---|---|
| P/E Ratio (TTM) | 22.07 | 38.63 | Chemed |
| Price-to-Book Ratio | 5.20 | 2.65 | Amedisys |
| Debt-to-Equity Ratio | 12.15 | 35.34 | Chemed |
| PEG Ratio | 17.23 | 19.43 | Chemed |
| EV/EBITDA | 14.10 | 13.52 | Amedisys |
| Profit Margin (TTM) | 11.56% | 3.56% | Chemed |
| Operating Margin (TTM) | 11.00% | 11.70% | Amedisys |
| EBITDA Margin (TTM) | 11.00% | 11.70% | Amedisys |
| Return on Equity | 24.14% | 6.67% | Chemed |
| Return on Assets (TTM) | 13.56% | 6.52% | Chemed |
| Free Cash Flow (TTM) | $367.97M | $214.29M | Chemed |
| Dividend Yield | 0.18% | N/A | N/A |
| 1-Year Return | -25.00% | 3.24% | Amedisys |
| Price-to-Sales Ratio (TTM) | 2.49 | 1.36 | Amedisys |
| Enterprise Value | $6.12B | $3.42B | Chemed |
| EV/Revenue Ratio | 2.44 | 1.42 | Amedisys |
| Gross Profit Margin (TTM) | 29.85% | 43.96% | Amedisys |
| Revenue per Share (TTM) | $170 | $73 | Chemed |
| Earnings per Share (Diluted) | $19.43 | $2.57 | Chemed |
| Beta (Stock Volatility) | 0.46 | 0.90 | Chemed |
Performance
Key Stats
Valuation
Financials
Short Interest
Dividends
Chemed vs Amedisys Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| Chemed | 0.10% | 4.18% | -6.56% | -23.50% | -21.37% | -17.54% |
| Amedisys | 0.06% | 2.47% | 3.35% | 6.03% | 9.68% | 11.05% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Chemed | -25.00% | -11.35% | -14.11% | 191.74% | 758.71% | 973.86% |
| Amedisys | 3.24% | -17.52% | -56.18% | 122.39% | 322.79% | 231.32% |
Performance & Financial Health Analysis: Chemed vs Amedisys
| Metric | CHE | AMED |
|---|---|---|
| Market Information | ||
| Market Cap | $6.25B | $3.27B |
| Market Cap Category | Mid cap | Mid cap |
| 10 Day Avg. Volume | 228,990 | 719,530 |
| 90 Day Avg. Volume | 207,240 | 516,367 |
| Last Close | $435.33 | $100.94 |
| 52 Week Range | $408.42 - $623.61 | $82.15 - $100.99 |
| % from 52W High | -30.19% | -0.05% |
| All-Time High | $654.62 (Mar 11, 2024) | $325.12 (Jan 25, 2021) |
| % from All-Time High | -33.50% | -68.95% |
| Growth Metrics | ||
| Quarterly Revenue Growth | 0.04% | 0.05% |
| Quarterly Earnings Growth | -0.26% | -0.13% |
| Financial Health | ||
| Profit Margin (TTM) | 0.12% | 0.04% |
| Operating Margin (TTM) | 0.11% | 0.12% |
| Return on Equity (TTM) | 0.24% | 0.07% |
| Debt to Equity (MRQ) | 12.15 | 35.34 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | $82.56 | $37.48 |
| Cash per Share (MRQ) | $17.22 | $10.26 |
| Operating Cash Flow (TTM) | $426.78M | $239.42M |
| Levered Free Cash Flow (TTM) | $290.24M | $300.69M |
| Dividends | ||
| Last 12-Month Dividend Yield | 0.18% | N/A |
| Last 12-Month Dividend | $1.00 | N/A |
Valuation & Enterprise Metrics Analysis: Chemed vs Amedisys
| Metric | CHE | AMED |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | 22.07 | 38.63 |
| Forward P/E | 17.23 | 19.43 |
| PEG Ratio | 17.23 | 19.43 |
| Price to Sales (TTM) | 2.49 | 1.36 |
| Price to Book (MRQ) | 5.20 | 2.65 |
| Market Capitalization | ||
| Market Capitalization | $6.25B | $3.27B |
| Enterprise Value | $6.12B | $3.42B |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | 2.44 | 1.42 |
| Enterprise to EBITDA | 14.10 | 13.52 |
| Risk & Other Metrics | ||
| Beta | 0.46 | 0.90 |
| Book Value per Share (MRQ) | $82.56 | $37.48 |
Financial Statements Comparison: Chemed vs Amedisys
Financial Metrics
Loading Financial Charts...
Revenue
EBITDA
Operating Margin
Free Cash Flow
Long Term Debt
Profit Margin
Current Ratio
Operating Cash Flow
Income Statement (MRQ)
| Metric (MRQ) | CHE | AMED |
|---|---|---|
| Revenue/Sales | $646.94M | $621.86M |
| Cost of Goods Sold | $430.53M | $348.47M |
| Gross Profit | $216.41M | $273.39M |
| Research & Development | N/A | N/A |
| Operating Income (EBIT) | $94.76M | $72.74M |
| EBITDA | $112.02M | $97.35M |
| Pre-Tax Income | $95.67M | $48.33M |
| Income Tax | $23.92M | $19.27M |
| Net Income (Profit) | $71.76M | $29.05M |
Balance Sheet & Liquidity Metrics (MRQ)
| Metric (MRQ) | CHE | AMED |
|---|---|---|
| Cash & Equivalents | $173.88M | $337.30M |
| Total Current Assets | $502.39M | $662.20M |
| Total Current Liabilities | $290.56M | $488.36M |
| Long-Term Debt | $102.08M | $386.83M |
| Total Shareholders Equity | $1.18B | $1.27B |
| Retained Earnings | $2.79B | $880.25M |
| Property, Plant & Equipment | $724.13M | $229.50M |
Cash Flow Statement Comparison (MRQ)
| Metric (MRQ) | CHE | AMED |
|---|---|---|
| Operating Cash Flow | $34.75M | $75.50M |
| Capital Expenditures | $112,000 | $-696,000 |
| Free Cash Flow | $19.46M | $66.29M |
| Debt Repayment | N/A | N/A |
| Common Stock Repurchase | $-33.22M | N/A |
Short Interest & Institutional Ownership Analysis
| Metric | CHE | AMED |
|---|---|---|
| Shares Short | 388,345 | 2.24M |
| Short Ratio | 1.95 | 4.66 |
| Short % of Float | 0.03% | 0.07% |
| Average Daily Volume (10 Day) | 228,990 | 719,530 |
| Average Daily Volume (90 Day) | 207,240 | 516,367 |
| Shares Outstanding | 14.56M | 32.78M |
| Float Shares | 14.27M | 32.24M |
| % Held by Insiders | 0.02% | 0.02% |
| % Held by Institutions | 0.97% | 0.93% |
Dividend Analysis & Yield Comparison: Chemed vs Amedisys
| Metric | CHE | AMED |
|---|---|---|
| Last 12-Month Dividend | $1.00 | N/A |
| Last 12-Month Dividend Yield | 0.18% | N/A |
| 3-Year Avg Annual Dividend | $1.37 | N/A |
| 3-Year Avg Dividend Yield | 0.08% | N/A |
| 3-Year Total Dividends | $4.10 | N/A |
| Ex-Dividend Date | Nov 18, 2024 | N/A |